84807-37-4

Usage

Uses

Used in Pharmaceutical Synthesis:
1-BOC-4-(2-Nitro,3-aminophenyl)-piperazin is used as a key intermediate in the development of pharmaceutical compounds. Its unique structure allows for the creation of a wide range of drug candidates with potential therapeutic applications.
Used in Agrochemical Development:
In the agrochemical industry, 1-BOC-4-(2-Nitro,3-aminophenyl)-piperazin serves as a crucial building block for the synthesis of various agrochemicals, contributing to the development of effective products for agricultural use.
Used in Medicinal Chemistry Research:
1-BOC-4-(2-NITRO,3-AMINOPHENYL)-PIPERAZINE is utilized in medicinal chemistry for the exploration and optimization of potential drug candidates. The presence of the BOC protective group, along with the nitro and amino groups, makes it an attractive intermediate for researchers to modify and enhance the properties of new pharmaceutical agents.
Overall, 1-BOC-4-(2-Nitro,3-aminophenyl)-piperazin is a versatile intermediate in the chemical and pharmaceutical industry, with broad applications in drug discovery and development, as well as in the agrochemical sector.

Upstream product

• 1046790-51-5 tert-butyl 4-(3-azido-2-nitrophenyl)piperazine-1-carboxylate 
• 59483-54-4 3-chloro-2-nitro-aniline 
• 75844-69-8 t-butyl piperidinecarboxylate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1046790-77-5 tert-butyl 4-{2-nitro-3-[(trifluoroacetyl)amino]phenyl}piperazine-1-carboxylate 
• 874279-78-4 tert-butyl 4-(2,3-diaminophenyl)piperazine-1-carboxylate 

Relevant academic research and scientific papers

Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design

The discovery of a highly potent and selective small molecule inhibitor 9 for in vitro target validation of MNK1/2 kinases is described. The aminopyrazine benzimidazole series was derived from an HTS hit and optimized by utilization of a docking model, conformation analysis, and binding pocket comparison against antitargets.

Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1

Several novel amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines were synthesized which had potent activity against HIV-1. The synthetic approaches adopted allowed for variation of the substitution pattern and resulting ch

2-Phenyl-4-piperazinylbenzimidazoles: Orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor

Antagonism of the gonadotropin releasing hormone (GnRH) receptor has shown positive clinical results in numerous reproductive tissue disorders such as endometriosis, prostate cancer and others. Traditional therapy has been limited to peptide agonists and

Chemical Compounds

The present invention provides compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to a chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of

CHEMICAL COMPOUNDS

The present invention provides compounds of Formula (I) comprising: including salts, solvates, and physiologically functional derivatives thereof, pharmaceutical formulations containing them, processes for their preparation, and methods of treatment using them.

CHEMICAL COMPOUNDS

The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind specifically to the chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 and/or CCR5 of a target cell.